• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

    9/10/25 9:40:00 AM ET
    $BGL
    $NTHI
    Metal Mining
    Basic Materials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGL alert in real time by email

    NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Blue Gold Limited (NASDAQ:BGL) ("Blue Gold" or the "Company"), a next-generation gold development and technology company, today announced the appointment of Sameer Salgar, Founding Partner and Chief Financial Officer of Quazar Investment, to its Advisory Board.

    Sameer brings over 20 years of investment, corporate finance, and strategic advisory experience. As co-founder of Quazar Investment, a UAE-based private investment firm, he has built a reputation for leading transformational cross-border transactions and connecting growth companies with global capital partners. His addition to the Advisory Board underscores Blue Gold's commitment to scaling its acquisition strategy, expanding its digital gold platform, and establishing ties to the UAE, one of the world's fast-growing financial centers.

    As Advisory Board member, Sameer and Quazar will:

    • Guide the rollout of digital technology solutions aligned with Blue Gold's Digital Gold Initiative.
    • Assist with the establishment of UAE-based gold deposit and vaulting infrastructure, enhancing security and scalability.
    • Facilitate introductions to regional capital providers, strengthening Blue Gold's access to growth funding and institutional partnerships.

    "I am excited to join Blue Gold's Advisory Board at such a pivotal time," said Sameer Salgar. "The Company's vision of combining world-class gold assets with innovative digital technologies aligns perfectly with Quazar's focus on global growth opportunities."

    Quazar Investment has advised on and participated in several high-profile international transactions, including its advisory participation in an $8 billion all-cash bid for Citgo Refining, a downstream energy asset, as well as a $50 million strategic partnership with NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) during its Nasdaq uplisting.

    "We are honored to welcome Sameer to Blue Gold's Advisory Board," said Andrew Cavaghan, Chief Executive Officer of Blue Gold. "As a seasoned executive and visionary business leader, he has consistently delivered on high-profile deals and demonstrated a deep understanding of capital markets. His experience and global network will add tremendous value as we scale our mining acquisitions and advance our Digital Gold Initiative."

    Gold remains a cornerstone of global finance, and demand for gold-backed digital products continues to expand. By combining real mining assets with a tokenized gold platform, Blue Gold aims to deliver shareholder growth while addressing the global need for secure, asset-backed digital currencies. The appointment of Sameer to the Advisory Board strengthens this vision, providing deal-making expertise and strategic UAE market connectivity.

    About Quazar Investment

    Quazar Investment, headquartered in the United Arab Emirates, is a private investment firm specializing in energy, infrastructure, and capital markets. Quazar has advised on high-profile international transactions, including major energy asset bids and advisory mandates for Nasdaq-listed companies. Leveraging its global network and strong presence in the UAE, Quazar helps companies access capital, technology, and market opportunities across key growth sectors.

    About Blue Gold Limited

    Blue Gold Limited (NASDAQ:BGL) is a next-generation gold development company focused on acquiring and aggregating high-potential mining assets across strategic global jurisdictions. The Company's mission is to unlock untapped value in the gold sector by combining disciplined resource acquisition with innovative monetization models, including asset-backed digital instruments. Blue Gold is committed to responsible development, operational transparency, and leveraging modern financial technologies to redefine how gold is produced, accessed, and owned in the 21st century.

    Blue Gold prioritizes growth, sustainable development, and transparency in all our business practices. We believe that our commitment to responsible mining will enable us to create value for our shareholders while minimizing our environmental footprint.



    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements include, but are not limited to: general economic or political conditions; negative economic conditions that could impact Blue Gold Limited and the gold industry in general; reduction in demand for Blue Gold Limited's products; changes in the markets that Blue Gold Limited targets; and any change in laws applicable to Blue Gold Limited or any regulatory or judicial interpretation.  As a result, we cannot assure you that the forward-looking statements included in this press release will prove to be accurate or correct. These and other important factors and risks are discussed in Blue Gold Limited's shell company report on Form 20-F, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 1, 2025, and other filings with the SEC.  In light of these risks, uncertainties, and assumptions, the future performance or events described in the forward-looking statements in this press release might not occur. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results, and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. Except as required by applicable law, we do not undertake any obligation to, and will not, update any forward-looking statements, whether as a result of new information, future events, or otherwise. For more information regarding Blue Gold Limited, please visit https://bluegoldmine.com.

    No Offer or Solicitation

    This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption.

    For Further Information Contact:

    Tavistock Communications

    BlueGold@tavistock.co.uk

    +44 20 7920 3150

    Skyline Corporate Communications Group, LLC

    Scott Powell, President

    1177 Avenue of the Americas, 5th Floor

    New York, NY. 10036

    Office: (646) 893-5835

    Email: info@skylineccg.com



    Primary Logo

    Get the next $BGL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BGL
    $NTHI

    CompanyDatePrice TargetRatingAnalyst
    NeOnc Technologies Holdings Inc.
    $NTHI
    5/19/2026$13.00Buy
    Alliance Global Partners
    NeOnc Technologies Holdings Inc.
    $NTHI
    5/18/2026$20.00Buy
    Maxim Group
    NeOnc Technologies Holdings Inc.
    $NTHI
    4/24/2026$15.00Buy
    BTIG Research
    More analyst ratings

    $BGL
    $NTHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Samuelson James F

    3 - Blue Gold Ltd (0002019435) (Issuer)

    6/2/26 4:15:02 PM ET
    $BGL
    Metal Mining
    Basic Materials

    President Heshmatpour Amir F bought $41,592 worth of shares (10,000 units at $4.16), increasing direct ownership by 0.33% to 3,072,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/4/26 2:08:58 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Gomes Gustavo

    3 - Blue Gold Ltd (0002019435) (Issuer)

    5/1/26 4:15:24 PM ET
    $BGL
    Metal Mining
    Basic Materials

    $BGL
    $NTHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Multi-Billion-Dollar Search for Better Glioblastoma Treatments

    DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad

    6/3/26 9:28:24 AM ET
    $BNTX
    $IBRX
    $KZIA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

    DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine. For investors, the

    6/1/26 9:05:00 AM ET
    $LLY
    $NTHI
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Next Great AI Revolution May Be Drug Delivery

    DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud infrastructure. Yet some of the most important long-term applications of AI may ultimately emerge inside healthcare, particularly in the development and delivery of advanced therapeutics. The biotechnology sector is rapidly entering a new era where AI is no longer just helping discover drugs, it is beginning to reshape how therapies are delivered, personalized, monitored, and commercialized. This shift could become most important in diseases involving the brain and central nervous system. That is

    5/29/26 9:05:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGL
    $NTHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on NeOnc Technologies Holdings with a new price target

    Alliance Global Partners initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $13.00

    5/19/26 8:31:51 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on NeOnc Technologies Holdings with a new price target

    Maxim Group initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $20.00

    5/18/26 8:44:12 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on NeOnc Technologies Holdings with a new price target

    BTIG Research initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $15.00

    4/24/26 8:06:10 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGL
    $NTHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $41,592 worth of shares (10,000 units at $4.16), increasing direct ownership by 0.33% to 3,072,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/4/26 2:08:58 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Heshmatpour Amir F bought $45,180 worth of shares (10,000 units at $4.52), increasing direct ownership by 0.33% to 3,062,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/28/26 6:00:05 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha bought $2,440 worth of shares (500 units at $4.88), increasing direct ownership by 0.37% to 134,760 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/24/26 6:10:07 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGL
    $NTHI
    SEC Filings

    View All

    SEC Form 6-K filed by Blue Gold Limited

    6-K - Blue Gold Ltd (0002019435) (Filer)

    6/1/26 9:27:00 AM ET
    $BGL
    Metal Mining
    Basic Materials

    SEC Form EFFECT filed by Blue Gold Limited

    EFFECT - Blue Gold Ltd (0002019435) (Filer)

    6/1/26 12:15:06 AM ET
    $BGL
    Metal Mining
    Basic Materials

    SEC Form EFFECT filed by Blue Gold Limited

    EFFECT - Blue Gold Ltd (0002019435) (Filer)

    6/1/26 12:15:11 AM ET
    $BGL
    Metal Mining
    Basic Materials

    $BGL
    $NTHI
    Leadership Updates

    Live Leadership Updates

    View All

    Blue Gold Appoints Capital Markets Veteran as Chief Financial Officer

    NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- Blue Gold Limited (NASDAQ:BGL) (NASDAQ:BGLWW) ("Blue Gold" or the "Company"), a gold mining company with the infrastructure to deliver gold from mine-to-wallet, today announced the appointment of James Samuelson as Chief Financial Officer, effective June 1, 2026.   Samuelson brings more than 25 years of experience in corporate finance, capital markets, mergers and acquisitions, and public company leadership across a broad range of industries. He has extensive experience advising and leading Nasdaq-listed and emerging growth companies through financings, uplist transactions, strategic acquisitions, operational scaling initiatives, and SEC complian

    5/28/26 8:30:00 AM ET
    $BGL
    Metal Mining
    Basic Materials

    NeOnc Technologies Appoints David Choi as Chief Accounting Officer

    CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, has appointed David Choi as Chief Accounting Officer. In this role, Mr. Choi is responsible for overseeing the Company's accounting, financial reporting, internal controls, and corporate governance functions as NeOnc advances its clinical-stage biotechnology platform and expands its global operations. "David's extensive expertise in technical accounting and financial reporting for public companies comes at a pivotal time for NeOnc," said

    3/13/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blue Gold Appoints Wesley Paul to Advisory Board to Support Institutional Adoption of Standard Gold Coin

    NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Blue Gold Limited (NASDAQ:BGL) ("Blue Gold" or the "Company"), a next-generation gold development and technology company, today announced the appointment of Wesley Paul to its Advisory Board. Mr. Paul will work with the Company to support institutional engagement and adoption of its Standard Gold Coin (SGC), as Blue Gold continues to build a trusted, institutionally credible digital gold ecosystem. Paul brings more than five decades of experience across global finance, investments, energy markets, governance and technology. He previously served as Managing Director and Global Head of Investments at J.P. Morgan, where he oversaw all investment ac

    2/10/26 8:00:00 AM ET
    $BGL
    Metal Mining
    Basic Materials

    $BGL
    $NTHI
    Financials

    Live finance-specific insights

    View All

    NeOnc Provides Business Update and Reports Q1 2026 Financial Results

    CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company advancing two Phase 2 programs in central nervous system (CNS) cancers, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent operational achievements and upcoming milestones. Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented: "The first quarter of 2026 marked a transformational period for NeOnc as we advanced both of our lead clinical programs toward important regulatory and value-creation milestones. We successfully comp

    5/18/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

    CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET. NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second

    3/4/26 8:00:00 AM ET
    $MRK
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

    CALABASAS, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced today announced that it will host an investor conference call and webcast on March 4, 2026, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time. During the call, members of the NeOnc management team and independent members of the Company's Scientific Advisory Board (SAB) will present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial, evaluating NeOnc's proprietary bioconjugated

    2/27/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care